跳转至内容
Merck

N-004

Supelco

纳洛酮 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价

选择尺寸

1 ML
$57.10

$57.10


请联系客服了解存货情况

获取大包装报价

选择尺寸

变更视图
1 ML
$57.10

About This Item

经验公式(希尔记法):
C19H21NO4
CAS号:
分子量:
327.37
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

$57.10


请联系客服了解存货情况

获取大包装报价

等级

certified reference material

质量水平

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

forensics and toxicology

包装形式

single component solution

储存温度

2-8°C

SMILES字符串

Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC=C

InChI

1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1

InChI key

UZHSEJADLWPNLE-GRGSLBFTSA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

一般描述

纳洛酮是一种阿片类药物,用于抵消阿片类药物过量的影响。该认证溶液标准适用于LC/MS或GC/MS应用,如临床毒理学和法医分析。纳洛酮以商品名Narcan®、Nalone和Narcan®ti销售。

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Narcan is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes,Central nervous system

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Jason Boland et al.
Clinical medicine (London, England), 13(2), 149-151 (2013-05-18)
Opioids can induce respiratory depression by invoking a centrally mediated decrease in involuntary respiratory rate, which in severe cases can cause a decrease in oxygen saturation. If respiratory depression is opioid induced, both low respiratory rate and low oxygen saturation
Anne M Neumann et al.
Journal of addictive diseases, 32(1), 68-78 (2013-03-14)
Patients with opioid addiction who receive prescription opioids for treatment of nonmalignant chronic pain present a therapeutic challenge. Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone. At the 6-month follow-up examination, 26 (48.1%)
R Terry Furst
Journal of addictive diseases, 32(1), 53-67 (2013-03-14)
This study explores strategies that Suboxone misusers utilize while in drug treatment. Ethnographic interviews were conducted with 14 patients who had cycled in and out of Suboxone treatment. The objective of the study is to identify strategies implemented by patients
Severe postoperative hyperthermic syndrome after addition of tilidine/naloxone to duloxetine therapy.
Marco Vinetti et al.
Clinical toxicology (Philadelphia, Pa.), 51(6), 516-517 (2013-06-19)
Robert Taylor et al.
Expert opinion on investigational drugs, 22(4), 517-525 (2013-03-15)
Opioid receptor antagonists are well known for their ability to attenuate or reverse the effects of opioid agonists. This property has made them useful in mitigating opioid side effects, overdose and abuse. Paradoxically, opioid antagonists have been reported to produce

商品

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

相关内容

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持